Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.

Qian Xie, Jing Wang, Wenwen Wu, Ye ZhaoPubMed 2022

TL;DR

This study investigates how apatinib (Apa) can overcome paclitaxel (PTX) resistance in gastric cancer (GC) cells. Researchers found that apatinib effectively reduces the proliferation, invasion, and migration of PTX-resistant GC cells by targeting the VEGFR2 pathway, offering a potential strategy to improve chemotherapy efficacy.

What Problem Does This Paper Address?

Drug resistance is a major hurdle in treating gastric cancer (GC), significantly limiting the effectiveness of chemotherapy. Paclitaxel (PTX), a common chemotherapy drug for GC, often loses its efficacy due to the development of resistance in cancer cells. Understanding the mechanisms behind this resistance and identifying ways to overcome it is crucial for improving patient outcomes. This paper specifically addresses the challenge of PTX resistance in GC and explores the potential of apatinib, a known anti-cancer drug, to reverse this resistance.

Methods

The researchers employed a multi-pronged approach to investigate the effects of apatinib on PTX-resistant GC cells:

  • Cell Line Development: They established a PTX-resistant GC cell line (MGC803/PTX) from the parent MGC803 cell line through a prolonged drug gradient induction method.
  • In Vitro Assays:
    • Cell Counting Kit-8 (CCK-8): Used to assess cell proliferation and determine the half-maximal inhibitory concentration (IC50) of PTX.
  • Transwell Assays: Employed to evaluate cell migration and invasion capabilities.
  • Plate Clone Formation Assay: Used to assess the proliferation capacity of cells.
  • Molecular Analysis:
    • Western Blot: Utilized to measure the protein levels of key molecules involved in apoptosis (Bcl-2, Bax), drug resistance (MDR1, P-gp), and the target pathway (VEGFR2).
  • Real-time quantitative polymerase chain reaction (RT-qPCR): Used to quantify the mRNA expression levels of VEGFR2.
  • Genetic Manipulation: VEGFR2 was overexpressed in MGC803/PTX cells to investigate its specific role in apatinib's effect on PTX resistance.

Datasets

Not discussed in the paper. The study primarily uses established cell lines and in vitro experimental models.

Key Insights and Ideas

  • PTX Resistance is Multifaceted: The development of PTX resistance in MGC803 cells was associated with increased expression of VEGFR2, MDR1, P-gp, and Bcl-2, alongside decreased Bax protein levels. This highlights a complex interplay of factors contributing to resistance.
  • VEGFR2 as a Key Player: The study strongly implicates VEGFR2 in PTX resistance. Overexpression of VEGFR2 in resistant cells not only accelerated proliferation but also appeared to counteract the beneficial effects of apatinib.
  • Apatinib as a Reversal Agent: Apatinib demonstrated a significant ability to reverse PTX resistance. It effectively reduced the proliferation, invasion, and migration of resistant cells.
  • VEGFR2 Pathway is the Target: The mechanism by which apatinib exerts its effect appears to be through the VEGFR2 signaling pathway. Apatinib's intervention led to a decrease in VEGFR2 expression, suggesting it directly targets this pathway to overcome resistance.

Key Results

  • Establishment of PTX-Resistant Cells: MGC803/PTX cells exhibited a 9.7-fold increase in PTX IC50 compared to parent MGC803 cells, confirming moderate drug resistance. These resistant cells also showed significantly reduced growth rates.
  • VEGFR2 Upregulation in Resistant Cells: Both mRNA and protein levels of VEGFR2 were significantly higher in MGC803/PTX cells compared to MGC803 cells.
  • Drug Resistance and Apoptosis Markers: In MGC803/PTX cells, MDR1, P-gp, and Bcl-2 protein levels were significantly increased, while Bax protein levels were decreased, indicating enhanced survival and reduced apoptosis.
  • Apatinib's Ameliorative Effects: Treatment with apatinib in MGC803/PTX cells led to:
  • Decreased cell migration, invasion, and proliferation.
  • Reduced levels of MDR1, P-gp, and VEGFR2.
  • Increased Bax protein levels, suggesting enhanced apoptosis.
  • VEGFR2 Overexpression Reverses Apatinib's Effect: Overexpressing VEGFR2 in MGC803/PTX cells partially offset the positive effects of apatinib, reinforcing VEGFR2's central role.

Limitations and Future Work

  • In Vitro Focus: The study was conducted entirely in vitro. The authors acknowledge this limitation and emphasize the need for future randomized animal experimental and clinical studies to validate these findings in a more complex biological context.
  • Clinical Translation: The researchers express a desire to explore whether apatinib can successfully reverse drug resistance in animal models and human subjects through clinical trials.
  • Broader Mechanisms: While the study strongly implicates the VEGFR2 pathway, it acknowledges that other mechanisms of PTX resistance exist (e.g., microtubule protein mutation, changes in Bcl-2 phosphorylation). Future work could explore the interplay of apatinib with these other resistance mechanisms.

Summary updated

Abstract

Drug resistance of gastric carcinoma (GC) is a burning question in the medical field. This study aimed to investigating the ameliorative effect of apatinib (Apa) on paclitaxel (PTX) resistance in GC. In this research, PTX-resistant MGC803 cells were intervened by Apa. Cell proliferation was detected by cell counting kit-8 (CCK-8) assay, and cell migration and invasion was determined by Transwell assays. The levels of apoptosis-related proteins (Bcl-2, Bax), drug resistance-related proteins (MDR1, P-gp) and VEGFR2 protein were measure by Western blot, and the mRNA expression of VEGFR2 was tested by real-time quantitative polymerase chain reaction (RT-qPCR). Then VEGFR2 was overexpressed to examine the role of Apa in PTX-resistant MGC803 cells. The results identified a significantly reduced growth rate of MGC803/PTX cells after PTX induction, obviously increased invasive and migrated cells, and evidently enhanced proliferation capacity of MGC803/PTX cells as compared to MGC803 cells. In MGC803/PTX cells, VEGFR2, MDR1, P-gp and Bcl-2 were all up-regulated while Bax was down-regulated. After Apa intervention, PTX-resistant MGC803 cells showed decreased cell migration, invasion and proliferation, reduced MDR1, P-gp and VEGFR2 levels, and increased Bax protein level. Overexpression of VEGFR2 can offset the rescue effect of Apa on PTX-induced drug resistance of MGC803 cells. Taken together, Apa may inhibit PTX resistance of MGC803 cells via the VEGFR2 signaling pathway.
BibTeX
@inproceedings{xie2022apatinib,
  author = {Qian Xie and Jing Wang and Wenwen Wu and Ye Zhao},
  title = {{Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.}},
  booktitle = {PubMed},
  year = {2022},
}
Figure